TP53-mutated Acute Myeloid Leukemia and Myelodysplastic Syndrome: Biology, Treatment Challenges, and Upcoming Approaches

Overview

Journal Ann Hematol

Specialty Hematology

Date 2023 Sep 28

PMID 37770618

Authors

Mariana Pinto Pereira

Elizabeth Herrity

Dennis D H Kim

Affiliations

Soon will be listed here.

Abstract

Improved understanding of TP53 biology and the clinicopathological features of TP53-mutated myeloid neoplasms has led to the recognition of TP53-mutated acute myeloid leukemia/myelodysplastic syndrome (TP53m AML/MDS) as a unique entity, characterized by dismal outcomes following conventional therapies. Several clinical trials have investigated combinations of emerging therapies for these patients with the poorest molecular prognosis among myeloid neoplasms. Although some emerging therapies have shown improvement in overall response rates, this has not translated into better overall survival, hence the notion that p53 remains an elusive target. New therapeutic strategies, including novel targeted therapies, immune checkpoint inhibitors, and monoclonal antibodies, represent a shift away from cytotoxic and hypomethylating-based therapies, towards approaches combining non-immune and novel immune therapeutic strategies. The triple combination of azacitidine and venetoclax with either magrolimab or eprenetapopt have demonstrated safety in early trials, with phase III trials currently underway, and promising interim clinical results. This review compiles background on TP53 biology, available and emerging therapies along with their mechanisms of action for the TP53m disease entity, current treatment challenges, and recently published data and status of ongoing clinical trials for TP53m AML/MDS.

Citing Articles

Epigenetics-targeted drugs: current paradigms and future challenges.

Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S Signal Transduct Target Ther. 2024; 9(1):332.

PMID: 39592582 PMC: 11627502. DOI: 10.1038/s41392-024-02039-0.

Mutation Status in Myelodysplastic Neoplasm and Acute Myeloid Leukemia: Impact of Reclassification Based on the 5th WHO and International Consensus Classification Criteria: A Korean Multicenter Study.

Kim H, Shin S, Lee J, Kim I, Kim B, Kim H Ann Lab Med. 2024; 45(2):160-169.

PMID: 39497415 PMC: 11788706. DOI: 10.3343/alm.2024.0351.

TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment.

Zhang L, Abro B, Campbell A, Ding Y Lab Med. 2024; 55(6):686-699.

PMID: 39001691 PMC: 11532620. DOI: 10.1093/labmed/lmae048.

Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms.

Niscola P, Gianfelici V, Giovannini M, Piccioni D, Mazzone C, de Fabritiis P Cancers (Basel). 2024; 16(8).

PMID: 38672645 PMC: 11048617. DOI: 10.3390/cancers16081563.

Targeted Combination Therapies: A New Frontier in the Treatment of TP53 and KRAS Mutation-Associated Cancers.

Kargbo R ACS Med Chem Lett. 2024; 15(1):15-16.

PMID: 38229755 PMC: 10788931. DOI: 10.1021/acsmedchemlett.3c00534.

References

Bowen D, Groves M, Burnett A, Patel Y, Allen C, Green C . TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia. 2008; 23(1):203-6. DOI: 10.1038/leu.2008.173. View

Grob T, Al Hinai A, Sanders M, Kavelaars F, Rijken M, Gradowska P . Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022; 139(15):2347-2354. PMC: 11022827. DOI: 10.1182/blood.2021014472. View

Haase D, Stevenson K, Neuberg D, Maciejewski J, Nazha A, Sekeres M . TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019; 33(7):1747-1758. PMC: 6609480. DOI: 10.1038/s41375-018-0351-2. View

Weinberg O, Siddon A, Madanat Y, Gagan J, Arber D, Dal Cin P . TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022; 6(9):2847-2853. PMC: 9092405. DOI: 10.1182/bloodadvances.2021006239. View

Wong T, Ramsingh G, Young A, Miller C, Touma W, Welch J . Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2014; 518(7540):552-555. PMC: 4403236. DOI: 10.1038/nature13968. View

Klimovich B, Merle N, Neumann M, Elmshauser S, Nist A, Mernberger M . p53 partial loss-of-function mutations sensitize to chemotherapy. Oncogene. 2021; 41(7):1011-1023. PMC: 8837531. DOI: 10.1038/s41388-021-02141-5. View

Lindsley R, Saber W, Mar B, Redd R, Wang T, Haagenson M . Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017; 376(6):536-547. PMC: 5438571. DOI: 10.1056/NEJMoa1611604. View

Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E . Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016; 7(12):14172-87. PMC: 4924706. DOI: 10.18632/oncotarget.7290. View

Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia T, Rausch C . Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021; 127(20):3772-3781. PMC: 10462434. DOI: 10.1002/cncr.33689. View

10.

Levine A . p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020; 20(8):471-480. DOI: 10.1038/s41568-020-0262-1. View

11.

Lakin N, Jackson S . Regulation of p53 in response to DNA damage. Oncogene. 2000; 18(53):7644-55. DOI: 10.1038/sj.onc.1203015. View

12.

Joerger A, Fersht A . The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol. 2010; 2(6):a000919. PMC: 2869527. DOI: 10.1101/cshperspect.a000919. View

13.

Kadia T, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K . TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016; 122(22):3484-3491. PMC: 5269552. DOI: 10.1002/cncr.30203. View

14.

Zhou X, Hao Q, Lu H . Mutant p53 in cancer therapy-the barrier or the path. J Mol Cell Biol. 2018; 11(4):293-305. PMC: 6487791. DOI: 10.1093/jmcb/mjy072. View

15.

Sabapathy K, Lane D . Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol. 2017; 15(1):13-30. DOI: 10.1038/nrclinonc.2017.151. View

16.

Honda R, Tanaka H, Yasuda H . Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1998; 420(1):25-7. DOI: 10.1016/s0014-5793(97)01480-4. View

17.

Momand J, Zambetti G, Olson D, George D, Levine A . The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992; 69(7):1237-45. DOI: 10.1016/0092-8674(92)90644-r. View

18.

Shirole N, Pal D, Kastenhuber E, Senturk S, Boroda J, Pisterzi P . exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions. Elife. 2016; 5. PMC: 5092050. DOI: 10.7554/eLife.17929. View

19.

Liu Y, Chen C, Xu Z, Scuoppo C, Rillahan C, Gao J . Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature. 2016; 531(7595):471-475. PMC: 4836395. DOI: 10.1038/nature17157. View

20.

Olivier M, Hollstein M, Hainaut P . TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010; 2(1):a001008. PMC: 2827900. DOI: 10.1101/cshperspect.a001008. View